Association_NN
of_IN
glucocorticoid_NN
insensitivity_NN
with_IN
increased_VBN
expression_NN
of_IN
glucocorticoid_NN
receptor_NN
beta_NN
._.

In_IN
many_JJ
chronic_JJ
inflammatory_JJ
disorders_NNS
,_,
glucocorticoid_NN
-LRB-_-LRB-
GC_NN
-RRB-_-RRB-
insensitivity_NN
is_VBZ
a_DT
challenging_JJ
clinical_JJ
problem_NN
associated_VBN
with_IN
life-threatening_JJ
disease_NN
progression_NN
._.

The_DT
molecular_JJ
basis_NN
of_IN
GC_NN
insensitivity_NN
,_,
however_RB
,_,
is_VBZ
unknown_JJ
._.

Alternative_JJ
splicing_NN
of_IN
the_DT
GC_NN
receptor_NN
-LRB-_-LRB-
R_NN
-RRB-_-RRB-
pre-messenger_NN
RNA_NN
generates_VBZ
a_DT
second_JJ
GCR_NN
,_,
termed_VBN
GCR-beta_NN
,_,
which_WDT
does_VBZ
not_RB
bind_VB
GCs_NNS
but_CC
antagonizes_VBZ
the_DT
transactivating_VBG
activity_NN
of_IN
the_DT
classic_JJ
GCR_NN
,_,
termed_VBN
GCR-alpha_NN
._.

In_IN
the_DT
current_JJ
study_NN
,_,
we_PRP
demonstrate_VBP
that_IN
GC-insensitive_JJ
asthma_NN
is_VBZ
associated_VBN
with_IN
a_DT
significantly_RB
higher_JJR
number_NN
of_IN
GCR-beta-immunoreactive_JJ
cells_NNS
in_IN
peripheral_JJ
blood_NN
than_IN
GC-sensitive_JJ
asthmatics_NNS
or_CC
normal_JJ
controls_NNS
._.

Furthermore_RB
,_,
we_PRP
show_VBP
that_IN
patients_NNS
with_IN
GC-insensitive_JJ
asthma_NN
have_VBP
cytokine-induced_JJ
abnormalities_NNS
in_IN
the_DT
DNA_NN
binding_NN
capability_NN
of_IN
the_DT
GCR_NN
._.

These_DT
abnormalities_NNS
can_MD
be_VB
reproduced_VBN
by_IN
transfection_NN
of_IN
cell_NN
lines_NNS
with_IN
the_DT
GCR-beta_NN
gene_NN
resulting_VBG
in_IN
significant_JJ
reduction_NN
of_IN
their_PRP$
GCR-alpha_NN
DNA_NN
binding_NN
capacity_NN
._.

We_PRP
conclude_VBP
that_IN
increased_VBN
expression_NN
of_IN
GCR-beta_NN
is_VBZ
cytokine_NN
inducible_JJ
and_CC
may_MD
account_VB
for_IN
GC_NN
insensitivity_NN
in_IN
this_DT
common_JJ
inflammatory_JJ
condition_NN
._.

